m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05806
 [1]
m6A modification OIP5-AS1 OIP5-AS1 METTL14 Methylation : m6A sites Direct Inhibition Non-coding RNA OIP5-AS1 MIR98  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
m6A Target OIP5 antisense RNA 1 (OIP5-AS1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator OIP5 antisense RNA 1 (OIP5-AS1) LncRNA View Details
Regulated Target MicroRNA 98 (MIR98) View Details
Crosstalk Relationship m6A  →  ncRNA Inhibition
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary METTL14 promotes tumorigenesis by regulating lncRNA OIP5 antisense RNA 1 (OIP5-AS1)/MicroRNA 98 (MIR98)/ADAMTS8 signaling in papillary thyroid cancer.
Responsed Disease Papillary thyroid cancer ICD-11: 2D10.1
 Disease Info 
Pathway Response MAPK signaling pathway hsa04010
Cell Process Cell proliferation
Cell migration
Cell invasion
Cell metastasis
In-vitro Model
 TPC-1 Thyroid gland papillary carcinoma Homo sapiens CVCL_6298
K1 Thyroid gland papillary carcinoma Homo sapiens CVCL_2537
In-vivo Model Mice were anesthetized with an intraperitoneal (i.p) injection of pentobarbital sodium (25 mg/kg) and placed on a surgical thermostator. Mice were randomly allocated. Then OIP5-AS1/pcDNA3.1-NC/OIP5-AS1 + si-ADAMTS8 was stably transfected into K1 cells, si-OIP5-AS1/si-NC/si-OIP5-AS1 + ADAMTS8 was stably transfected into TPC-1 cells. Transfected cells were then injected into 4-week-old female BALB/c nude mice (n = 6/per group) at a density of 1 × 106 cells,
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2D10: Thyroid Cancer 12 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Lenvatinib Approved [2]
Synonyms
E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide
    Click to Show/Hide
External Link
CID: 9823820
TTD: D0R0FO
DrugBank: DB09078
 Compound Name Cabozantinib Approved [3]
Synonyms
Cabometyx; Cometriq
    Click to Show/Hide
External Link
CID: 25102847
TTD: D0IQ6P
DrugBank: DB08875
 Compound Name Thyrotropin Alfa Approved [4]
External Link
TTD: D0H4TQ
 Compound Name Selpercatinib Approved [5]
Synonyms
MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636
    Click to Show/Hide
External Link
CID: 134823904
TTD: D01KOA
 Compound Name Selumetinib Phase 3 [6]
Synonyms
AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U
    Click to Show/Hide
External Link
CID: 10127622
TTD: D0T5DP
DrugBank: DB11689
 Compound Name QGE-031 Phase 2 [7]
External Link
TTD: D0J7CH
 Compound Name GI-6207 Phase 2 [8]
External Link
TTD: D0L7VC
 Compound Name AIC100 Phase 1 [9]
External Link
TTD: DP0NU9
 Compound Name CYTO-403 Phase 1 [10]
External Link
TTD: DB2R5Y
 Compound Name Demogastrin Phase 1 [11]
Synonyms
Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2
    Click to Show/Hide
External Link
TTD: D0QJ6L
 Compound Name Recombinant TSH superagonists Investigative [12]
Synonyms
Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen
    Click to Show/Hide
External Link
TTD: D0U2DY
 Compound Name ITRI-305 Investigative [13]
Synonyms
RET tyrosine kinase inhibitors, Industrial Technology Research Institute
    Click to Show/Hide
External Link
TTD: D0N5TB
References
Ref 1 METTL14 promotes tumorigenesis by regulating lncRNA OIP5-AS1/miR-98/ADAMTS8 signaling in papillary thyroid cancer. Cell Death Dis. 2021 Jun 15;12(6):617. doi: 10.1038/s41419-021-03891-6.
Ref 2 FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 208627.
Ref 3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5887).
Ref 4 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020898.
Ref 5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
Ref 6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 7 ClinicalTrials.gov (NCT02336425) Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma. U.S. National Institutes of Health.
Ref 8 ClinicalTrials.gov (NCT01856920) A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer. U.S. National Institutes of Health.
Ref 9 ClinicalTrials.gov (NCT04420754) Study of AIC100 in Relapsed/Refractory Thyroid Cancer. U.S. National Institutes of Health.
Ref 10 Clinical pipeline report, company report or official report of Cytocom
Ref 11 99mTc-Demogastrin 2 for CCK 2-receptor scintigraphy in medullary thyroid carcinoma. J Nucl Med. 2008; 49 (Supplement 1):115P.
Ref 12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 255).
Ref 13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).